A clinical trial to compare the preventive effects of Atorvastatin and Rosuvasatin on kidney damage in patients undergoing cardiac surgery
Phase 4
- Conditions
- Health Condition 1: I700- Atherosclerosis of aorta
- Registration Number
- CTRI/2023/08/056801
- Lead Sponsor
- Sreeja Nittoori
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients of either gender aged between 18 and 70 years 2. Patients on stable dose of statins 3. Patients posted for PTCA requiring = 100ml contrast
Exclusion Criteria
1. Patients with high-risk features like cardiogenic shock, acute pulmonary edema and bleeding complications 2. ESRD requiring dialysis 3. Patients who have received intravenous contrast in the last 2 weeks 4. contraindications to statin treatment 5. patients on concomitant use of potential nephrotoxic agents 6. pregnancy and lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Change in serum creatinine levels & eGFR after pre-treatment with Atorvastatin & Rosuvastatin. <br/ ><br>2. Change in Cystatin-C levels after pre-treatment with Atorvastatin & Rosuvastatin.Timepoint: 1. Change in serum creatinine levels & eGFR in 48hrs after pre-treatment with Atorvastatin & Rosuvastatin. <br/ ><br>2. Change in Cystatin-C levels in 24hrs after pre-treatment with Atorvastatin and Rosuvastatin.
- Secondary Outcome Measures
Name Time Method 1. Proportion of patients showing Adverse Drug Reactions to high dose <br/ ><br>Atorvastatin & Rosuvastatin. <br/ ><br>2. Incidence of CIN after pre-treatment with Atorvastatin & Rosuvastatin.Timepoint: Incidence of CIN in 48hrs after pre-treatment with Atorvastatin and <br/ ><br>Rosuvastatin.